{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:07:08Z","timestamp":1758931628922,"version":"3.44.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006309","name":"American Parkinson Disease Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006309","id-type":"DOI","asserted-by":"crossref"}]},{"name":"American Academy of Neurology Clinical Research Training Scholarship in Parkinson\u2019s Disease"},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH grants NS110436, NS097799, NS075321"],"award-info":[{"award-number":["NIH grants NS110436, NS097799, NS075321"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17658-y","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:56:07Z","timestamp":1758884167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of small molecule dimethyoxyphenyl piperazine inhibitors of alpha-synuclein fibril growth"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6907-1702","authenticated-orcid":false,"given":"Helen","family":"Hwang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0096-1085","authenticated-orcid":false,"given":"Dhruva D.","family":"Dhavale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Guduputi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"John M.","family":"Beale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-3344","authenticated-orcid":false,"given":"Nigel J.","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7155-114X","authenticated-orcid":false,"given":"Paul T.","family":"Kotzbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"17658_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/35081564","volume":"2","author":"M Goedert","year":"2001","unstructured":"Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492\u2013501 (2001).","journal-title":"Nat. Rev. Neurosci."},{"key":"17658_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41589-020-0480-6","volume":"16","author":"RW Newberry","year":"2020","unstructured":"Newberry, R. W., Leong, J. T., Chow, E. D., Kampmann, M. & DeGrado, W. F. Deep mutational scanning reveals the structural basis for \u03b1-synuclein activity. Nat. Chem. Biol. 16, 653\u2013659 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"17658_CR3","doi-asserted-by":"publisher","first-page":"8331","DOI":"10.1073\/pnas.0400553101","volume":"101","author":"CC Jao","year":"2004","unstructured":"Jao, C. C., Der-Sarkissian, A., Chen, J. & Langen, R. Structure of membrane-bound \u03b1-synuclein studied by site-directed spin labeling. Proc. Natl. Acad. Sci. 101, 8331\u20138336 (2004).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"17658_CR4","doi-asserted-by":"publisher","first-page":"9595","DOI":"10.1074\/jbc.M411805200","volume":"280","author":"TS Ulmer","year":"2005","unstructured":"Ulmer, T. S., Bax, A., Cole, N. B. & Nussbaum, R. L. Structure and dynamics of micelle-bound human \u03b1-synuclein. J. Biol. Chem. 280, 9595\u20139603 (2005).","journal-title":"J. Biol. Chem."},{"key":"17658_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel, H. A., Overk, C. R., Oueslati, A. & Masliah, E. The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38\u201348 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"17658_CR6","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos, M. H. et al. Mutation in the \u03b1-synuclein gene identified in families with parkinson\u2019s disease. Sci. (80-). 276, 2045\u20132047 (1997).","journal-title":"Sci. (80-)"},{"key":"17658_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.expneurol.2004.01.007","volume":"187","author":"PT Kotzbauer","year":"2004","unstructured":"Kotzbauer, P. T. et al. Fibrillization of \u03b1-synuclein and Tau in Familial parkinson\u2019s disease caused by the A53T \u03b1-synuclein mutation. Exp. Neurol. 187, 279\u2013288 (2004).","journal-title":"Exp. Neurol."},{"key":"17658_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ana.10795","volume":"55","author":"JJ Zarranz","year":"2004","unstructured":"Zarranz, J. J. et al. The new mutation, E46K, of \u03b1-Synuclein causes Parkinson and lewy body dementia. Ann. Neurol. 55, 164\u2013173 (2004).","journal-title":"Ann. Neurol."},{"key":"17658_CR9","doi-asserted-by":"publisher","first-page":"10481","DOI":"10.1073\/pnas.1804198115","volume":"115","author":"J Pujols","year":"2018","unstructured":"Pujols, J. et al. Small molecule inhibits \u03b1-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Proc. Natl. Acad. Sci. 115, 10481\u201310486 (2018).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"17658_CR10","doi-asserted-by":"publisher","first-page":"101902","DOI":"10.1016\/j.jbc.2022.101902","volume":"298","author":"S Pe\u00f1a-D\u00edaz","year":"2022","unstructured":"Pe\u00f1a-D\u00edaz, S. et al. The small aromatic compound SynuClean-D inhibits the aggregation and seeded polymerization of multiple \u03b1-synuclein strains. J Biol. Chem 298(5), https:\/\/doi.org\/10.1016\/j.jbc.2022.101902. 101902 (2022).","journal-title":"J Biol. Chem"},{"key":"17658_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41598-021-04131-9","volume":"12","author":"M Hideshima","year":"2022","unstructured":"Hideshima, M. et al. Two-step screening method to identify \u03b1-synuclein aggregation inhibitors for parkinson\u2019s disease. Sci. Rep. 12, 351 (2022).","journal-title":"Sci. Rep."},{"key":"17658_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/PRA.0000000000000237","author":"LD Fryml","year":"2017","unstructured":"Fryml, L. D. et al. The role of amantadine withdrawal in 3 cases of treatment-refractory altered mental status. J. Psychiatr Pract. https:\/\/doi.org\/10.1097\/PRA.0000000000000237 (2017).","journal-title":"J. Psychiatr Pract."},{"key":"17658_CR13","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1080\/14756366.2020.1816999","volume":"35","author":"S Vittorio","year":"2020","unstructured":"Vittorio, S. et al. Rational design of small molecules able to inhibit \u03b1-synuclein amyloid aggregation for the treatment of parkinson\u2019s disease. J. Enzyme Inhib. Med. Chem. 35, 1727\u20131735 (2020).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"17658_CR14","doi-asserted-by":"crossref","unstructured":"Murray, K. A. et al. Small molecules disaggregate alpha-synuclein and prevent seeding from patient brain-derived fibrils. Proc. Natl. Acad. Sci. 120, e2217835120 (2023).","DOI":"10.1073\/pnas.2217835120"},{"key":"17658_CR15","doi-asserted-by":"publisher","first-page":"117613","DOI":"10.1016\/j.bmc.2024.117613","volume":"100","author":"AA Elbatrawy","year":"2024","unstructured":"Elbatrawy, A. A. et al. Discovery of small molecule benzothiazole and Indole derivatives tackling Tau 2N4R and \u03b1-synuclein fibrils. Bioorg. Med. Chem. 100, 117613 (2024).","journal-title":"Bioorg. Med. Chem."},{"key":"17658_CR16","doi-asserted-by":"publisher","first-page":"537139","DOI":"10.3389\/fnins.2020.00398","volume":"14","author":"TR Yamasaki","year":"2020","unstructured":"Yamasaki, T. R., Ono, K., Ho, L. & Pasinetti, G. M. Gut microbiome-modified polyphenolic compounds inhibit \u03b1-synuclein seeding and spreading in \u03b1-synucleinopathies. Front. Neurosci. 14, 537139 (2020).","journal-title":"Front. Neurosci."},{"key":"17658_CR17","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/acs.biochem.2c00207","volume":"61","author":"CH Tran","year":"2022","unstructured":"Tran, C. H., Saha, R., Blanco, C., Bagchi, D. & Chen, I. A. Modulation of \u03b1-Synuclein aggregation in vitro by a DNA aptamer. Biochemistry 61, 1757\u20131765 (2022).","journal-title":"Biochemistry"},{"key":"17658_CR18","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.1073\/pnas.0910723107","volume":"107","author":"J Bieschke","year":"2010","unstructured":"Bieschke, J. et al. EGCG remodels mature \u03b1-synuclein and amyloid-\u03b2 fibrils and reduces cellular toxicity. Proc. Natl. Acad. Sci. 107, 7710\u20137715 (2010).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"17658_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jmb.2009.10.068","volume":"395","author":"Y Yamaguchi","year":"2010","unstructured":"Yamaguchi, Y. et al. Characterization of inhibitor-bound \u03b1-synuclein dimer: role of \u03b1-synuclein N-terminal region in dimerization and inhibitor binding. J. Mol. Biol. 395, 445\u2013456 (2010).","journal-title":"J. Mol. Biol."},{"key":"17658_CR20","doi-asserted-by":"crossref","unstructured":"Caruana, G. et al. Inhibition and disaggregation of \u03b1-synuclein oligomers by natural polyphenolic compounds. (2011).","DOI":"10.1016\/j.febslet.2011.03.046"},{"key":"17658_CR21","doi-asserted-by":"publisher","first-page":"10624","DOI":"10.1021\/bi2012383","volume":"50","author":"G Grelle","year":"2011","unstructured":"Grelle, G. et al. Black tea Theaflavins inhibit formation of toxic amyloid-\u03b2 and \u03b1-synuclein fibrils. Biochemistry 50, 10624\u201310636 (2011).","journal-title":"Biochemistry"},{"key":"17658_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/nu8060367","volume":"8","author":"H Temsamani","year":"2016","unstructured":"Temsamani, H. et al. Piceatannol and other wine stilbenes: a pool of inhibitors against \u03b1-synuclein aggregation and cytotoxicity. Nutrients 8, 367 (2016).","journal-title":"Nutrients"},{"key":"17658_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nsmb.1437","volume":"15","author":"DE Ehrnhoefer","year":"2008","unstructured":"Ehrnhoefer, D. E. et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15, 558\u2013566 (2008).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"17658_CR24","doi-asserted-by":"publisher","first-page":"7722","DOI":"10.1021\/acs.jafc.6b03217","volume":"64","author":"R Hornedo-Ortega","year":"2016","unstructured":"Hornedo-Ortega, R. et al. Protocatechuic acid: Inhibition of fibril formation, destabilization of preformed fibrils of amyloid-\u03b2 and \u03b1-synuclein, and neuroprotection. J. Agric. Food Chem. 64, 7722\u20137732 (2016).","journal-title":"J. Agric. Food Chem."},{"key":"17658_CR25","doi-asserted-by":"publisher","first-page":"8337","DOI":"10.1038\/s41598-018-26645-5","volume":"8","author":"L Palazzi","year":"2018","unstructured":"Palazzi, L. et al. Oleuropein aglycone stabilizes the monomeric \u03b1-synuclein and favours the growth of non-toxic aggregates. Sci. Rep. 8, 8337 (2018).","journal-title":"Sci. Rep."},{"key":"17658_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.fct.2018.06.059","volume":"120","author":"R Hornedo-Ortega","year":"2018","unstructured":"Hornedo-Ortega, R., Cerezo, A. B., Troncoso, A. M. & Garcia-Parrilla, M. C. Protective effects of Hydroxytyrosol against \u03b1-synuclein toxicity on PC12 cells and fibril formation. Food Chem. Toxicol. 120, 41\u201349 (2018).","journal-title":"Food Chem. Toxicol."},{"key":"17658_CR27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.bbrc.2007.11.075","volume":"365","author":"EHM Charbel","year":"2008","unstructured":"Charbel, E. H. M., Mahmoodian, F., Tomita, Y. & Sidhu, A. Dopamine differentially induces aggregation of A53T mutant and wild type a-synuclein: insights into the protein chemistry of parkinson\u2019s disease. Biochem. Biophys. Res. Commun. 365, 833\u2013839 (2008).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"17658_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1471-4159.2006.03707.x","volume":"97","author":"K Ono","year":"2006","unstructured":"Ono, K. & Yamada, M. Antioxidant compounds have potent anti-fibrillogenic and fibril\u2010destabilizing effects for \u03b1\u2010synuclein fibrils in vitro. J. Neurochem. 97, 105\u2013115 (2006).","journal-title":"J. Neurochem"},{"key":"17658_CR29","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1111\/j.1742-4658.2005.04792.x","volume":"272","author":"H Li","year":"2005","unstructured":"Li, H. et al. Inhibition of \u03b1-synuclein fibrillization by dopamine analogs via reaction with the amino groups of \u03b1\u2010synuclein: implication for dopaminergic neurodegeneration. FEBS J. 272, 3661\u20133672 (2005).","journal-title":"FEBS J."},{"key":"17658_CR30","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1021\/bi0600749","volume":"45","author":"M Masuda","year":"2006","unstructured":"Masuda, M. et al. Small molecule inhibitors of \u03b1-synuclein filament assembly. Biochemistry 45, 6085\u20136094 (2006).","journal-title":"Biochemistry"},{"key":"17658_CR31","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.chembiol.2004.08.025","volume":"11","author":"J Li","year":"2004","unstructured":"Li, J., Zhu, M., Rajamani, S., Uversky, V. N. & Fink, A. L. Rifampicin inhibits \u03b1-synuclein fibrillation and disaggregates fibrils. Chem. Biol. 11, 1513\u20131521 (2004).","journal-title":"Chem. Biol."},{"key":"17658_CR32","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.ejmech.2017.10.002","volume":"143","author":"N Ahsan","year":"2018","unstructured":"Ahsan, N., Siddique, I. A., Gupta, S. & Surolia, A. A routinely used protein staining dye acts as an inhibitor of wild type and mutant alpha-synuclein aggregation and modulator of neurotoxicity. Eur. J. Med. Chem. 143, 1174\u20131184 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"17658_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbrc.2014.10.062","volume":"454","author":"Y Liu","year":"2014","unstructured":"Liu, Y. et al. Hemin as a generic and potent protein misfolding inhibitor. Biochem. Biophys. Res. Commun. 454, 295\u2013300 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"17658_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nchem.2129","volume":"7","author":"LM Young","year":"2015","unstructured":"Young, L. M. et al. Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry\u2013mass spectrometry. Nat. Chem. 7, 73\u201381 (2015).","journal-title":"Nat. Chem."},{"key":"17658_CR35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/138161212798919093","volume":"18","author":"B Shrikanth Gadad","year":"2012","unstructured":"Shrikanth Gadad, B., Subramanya, K., Pullabhatla, P., Shantharam, S. S., KS, R. & I. & Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits \u03b1-synuclein oligomer formation: relevance to parkinson\u2019s disease. Curr. Pharm. Des. 18, 76\u201384 (2012).","journal-title":"Curr. Pharm. Des."},{"key":"17658_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.nbd.2014.11.007","volume":"74","author":"MT Ardah","year":"2015","unstructured":"Ardah, M. T. et al. Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. Neurobiol. Dis. 74, 89\u2013101 (2015).","journal-title":"Neurobiol. Dis."},{"key":"17658_CR37","doi-asserted-by":"publisher","first-page":"86640","DOI":"10.1039\/C6RA17770K","volume":"6","author":"M Liao","year":"2016","unstructured":"Liao, M., Zhao, Y., Huang, L., Cheng, B. & Huang, K. Isoliquiritigenin and liquiritin from glycyrrhiza uralensis inhibit \u03b1-synuclein amyloid formation. RSC Adv. 6, 86640\u201386649 (2016).","journal-title":"RSC Adv."},{"key":"17658_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuint.2012.10.001","volume":"62","author":"FL da Silva","year":"2013","unstructured":"da Silva, F. L. et al. Vitamins K interact with N-terminus \u03b1-synuclein and modulate the protein fibrillization in vitro. Exploring the interaction between Quinones and \u03b1-synuclein. Neurochem Int. 62, 103\u2013112 (2013).","journal-title":"Neurochem Int."},{"key":"17658_CR39","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1039\/C5FO00664C","volume":"7","author":"K Ji","year":"2016","unstructured":"Ji, K. et al. Inhibition effects of Tanshinone on the aggregation of \u03b1-synuclein. Food Funct. 7, 409\u2013416 (2016).","journal-title":"Food Funct."},{"key":"17658_CR40","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1093\/brain\/aww238","volume":"139","author":"W Wrasidlo","year":"2016","unstructured":"Wrasidlo, W. et al. A de Novo compound targeting \u03b1-synuclein improves deficits in models of parkinson\u2019s disease. Brain 139, 3217\u20133236 (2016).","journal-title":"Brain"},{"key":"17658_CR41","doi-asserted-by":"publisher","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","volume":"8","author":"DL Price","year":"2018","unstructured":"Price, D. L. et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of parkinson\u2019s disease. Sci. Rep. 8, 16165 (2018).","journal-title":"Sci. Rep."},{"key":"17658_CR42","doi-asserted-by":"publisher","first-page":"11897","DOI":"10.1074\/jbc.M113.542340","volume":"289","author":"ME Herva","year":"2014","unstructured":"Herva, M. E. et al. Anti-amyloid compounds inhibit \u03b1-synuclein aggregation induced by protein misfolding Cyclic amplification (PMCA). J. Biol. Chem. 289, 11897\u201311905 (2014).","journal-title":"J. Biol. Chem."},{"key":"17658_CR43","doi-asserted-by":"publisher","first-page":"9034","DOI":"10.1074\/jbc.M116.767053","volume":"292","author":"DD Dhavale","year":"2017","unstructured":"Dhavale, D. D. et al. A sensitive assay reveals structural requirements for \u03b1-synuclein fibril growth. J. Biol. Chem. 292, 9034\u20139050 (2017).","journal-title":"J. Biol. Chem."},{"key":"17658_CR44","doi-asserted-by":"publisher","unstructured":"Dhavale, D. D. et al. Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue. bioRxiv 2023.01.09.523303 (2023). https:\/\/doi.org\/10.1101\/2023.01.09.523303","DOI":"10.1101\/2023.01.09.523303"},{"key":"17658_CR45","doi-asserted-by":"publisher","first-page":"13428","DOI":"10.3390\/ijms232113428","volume":"23","author":"I Sedov","year":"2022","unstructured":"Sedov, I. & Khaibrakhmanova, D. Molecular mechanisms of Inhibition of protein amyloid fibril formation: evidence and perspectives based on kinetic models. Int. J. Mol. Sci. 23, 13428 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"17658_CR46","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jmb.2019.11.019","volume":"432","author":"K Afitska","year":"2020","unstructured":"Afitska, K., Priss, A., Yushchenko, D. A. & Shvadchak, V. V. Structural optimization of inhibitors of \u03b1-synuclein fibril growth: affinity to the fibril end as a crucial factor. J. Mol. Biol. 432, 967\u2013977 (2020).","journal-title":"J. Mol. Biol."},{"key":"17658_CR47","doi-asserted-by":"publisher","first-page":"e0196056","DOI":"10.1371\/journal.pone.0196056","volume":"13","author":"LB Lassen","year":"2018","unstructured":"Lassen, L. B. et al. ELISA method to detect \u03b1-synuclein oligomers in cell and animal models. PLoS One. 13, e0196056 (2018).","journal-title":"PLoS One"},{"key":"17658_CR48","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-05319-3","volume":"610","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Structures of \u03b1-synuclein filaments from human brains with lewy pathology. Nature 610, 791\u2013795 (2022).","journal-title":"Nature"},{"key":"17658_CR49","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1038\/s41467-024-46832-5","volume":"15","author":"DD Dhavale","year":"2024","unstructured":"Dhavale, D. D. et al. Structure of alpha-synuclein fibrils derived from human lewy body dementia tissue. Nat. Commun. 15, 2750 (2024).","journal-title":"Nat. Commun."},{"key":"17658_CR50","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt, J., Santos-Martins, D., Tillack, A. F. & Forli, S. AutoDock Vina 1.2. 0: new Docking methods, expanded force field, and python bindings. J. Chem. Inf. Model. 61, 3891\u20133898 (2021).","journal-title":"J. Chem. Inf. Model."},{"key":"17658_CR51","doi-asserted-by":"publisher","first-page":"719","DOI":"10.21037\/atm.2020.01.117","volume":"8","author":"G Bitan","year":"2020","unstructured":"Bitan, G. The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question\u2014are polyphenols a viable therapeutic option against proteinopathies? Ann Transl Med 8, https:\/\/doi.org\/10.21037\/atm.2020.01.117719. (2020).","journal-title":"Ann Transl Med"},{"key":"17658_CR52","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S1474-4422(19)30141-3","volume":"18","author":"J Levin","year":"2019","unstructured":"Levin, J. et al. Safety and efficacy of Epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 18, 724\u2013735 (2019).","journal-title":"Lancet Neurol."},{"key":"17658_CR53","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/mds.29170","volume":"37","author":"JW Smit","year":"2022","unstructured":"Smit, J. W. et al. Phase 1\/1b studies of UCB0599, an oral inhibitor of \u03b1-Synuclein misfolding, including a randomized study in parkinson\u2019s disease. Mov. Disord. 37, 2045\u20132056 (2022).","journal-title":"Mov. Disord"},{"key":"17658_CR54","doi-asserted-by":"publisher","first-page":"113637","DOI":"10.1016\/j.biopha.2022.113637","volume":"154","author":"S Kim","year":"2022","unstructured":"Kim, S. et al. Inhibition of \u03b1-synuclein aggregation by MT101-5 is neuroprotective in mouse models of parkinson\u2019s disease. Biomed. Pharmacother. 154, 113637 (2022).","journal-title":"Biomed. Pharmacother"},{"key":"17658_CR55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ymeth.2023.04.002","volume":"214","author":"R Dervi\u015fo\u011flu","year":"2023","unstructured":"Dervi\u015fo\u011flu, R. et al. Anle138b interaction in \u03b1-synuclein aggregates by dynamic nuclear polarization NMR. Methods 214, 18\u201327 (2023).","journal-title":"Methods"},{"key":"17658_CR56","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner, J. et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and parkinson\u2019s disease. Acta Neuropathol. 125, 795\u2013813 (2013).","journal-title":"Acta Neuropathol."},{"key":"17658_CR57","doi-asserted-by":"publisher","first-page":"10727","DOI":"10.1074\/jbc.M113.524520","volume":"289","author":"S Acharya","year":"2014","unstructured":"Acharya, S. et al. Molecular basis for preventing \u03b1-synuclein aggregation by a molecular tweezer. J. Biol. Chem. 289, 10727\u201310737 (2014).","journal-title":"J. Biol. Chem."},{"key":"17658_CR58","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/ja206279b","volume":"133","author":"S Sinha","year":"2011","unstructured":"Sinha, S. et al. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J. Am. Chem. Soc. 133, 16958\u201316969 (2011).","journal-title":"J. Am. Chem. Soc."},{"key":"17658_CR59","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s13311-012-0105-1","volume":"9","author":"S Prabhudesai","year":"2012","unstructured":"Prabhudesai, S. et al. A novel molecular tweezer inhibitor of \u03b1-synuclein neurotoxicity in vitro and in vivo. Neurotherapeutics 9, 464\u2013476 (2012).","journal-title":"Neurotherapeutics"},{"key":"17658_CR60","doi-asserted-by":"publisher","first-page":"165513","DOI":"10.1016\/j.bbadis.2019.07.007","volume":"1865","author":"M Herrera-Vaquero","year":"2019","unstructured":"Herrera-Vaquero, M. et al. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent \u03b1-synuclein in experimental multiple system atrophy. Biochim. Biophys. Acta (BBA)-Molecular Basis Dis. 1865, 165513 (2019).","journal-title":"Biochim. Biophys. Acta (BBA)-Molecular Basis Dis."},{"key":"17658_CR61","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/acn3.51482","volume":"9","author":"RL Miller","year":"2022","unstructured":"Miller, R. L. et al. Quantifying regional \u03b1-synuclein, amyloid \u03b2, and Tau accumulation in lewy body dementia. Ann. Clin. Transl Neurol. 9, 106\u2013121 (2022).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"17658_CR62","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jsb.2017.02.003","volume":"198","author":"S He","year":"2017","unstructured":"He, S. & Scheres, S. H. W. Helical reconstruction in RELION. J. Struct. Biol. 198, 163\u2013176 (2017).","journal-title":"J. Struct. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17658-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17658-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17658-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:03:46Z","timestamp":1758884626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17658-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17658"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17658-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Competing Interests Statement: Authors HH, DDD, and PTK have a pending patent application \u201cCompounds that Inhibit Alpha-Synuclein Fibril Growth for the Treatment of Parkinson\u2019s Disease\u201d. Patent applicant: Washington University in St. Louis, Name of inventors: Paul T. Kotzbauer, Helen Hwang, and Dhruva D. Dhavale. Status of application: Pending. The patent application covers the dimethyoxyphenyl piperazine and related compounds that can inhibit asyn fibril growth. In addition, authors DDD and PTK have a pending patent application titled \u201cTissue-Seeded Fibrils and Methods of Making and Using Same\u201d. Patent applicant: Washington University in St. Louis, Name of inventors: Paul T. Kotzbauer, Dhruva D. Dhavale, Rebecca Miller and Jennifer Y. O\u2019Shea, Application number: 17\/858817, Status of application: Pending. The patent application covers the process of generating amplified fibrils, its methods and composition. Authors DDD and PTK are founders of Helical Biosciences LLC and have an ownership interest in the company. Other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33108"}}